The 3rd Annual International Congress of Biotherapy - Japan (ICB-Japan 2019)
Highlights of the Conference

● 1 Plenary Forum from a Panel of Leading Experts in Biotherapy
● 50+ Project Posters on Medical Research, Clinical Research & Discovery
● 150+ Oral Presentations on the Latest Biotherapy Development
● 300+ Professional Attendees from All over the World for Unrivalled Networking
● Opportunity to Present Your Work and Forge New Collaborations
● Tech Tour to Famous Science Spots & Cultural Landscapes in Osaka

About the Conference

In recent years, with the development of cell biology, immunology and other disciplines, biological therapy technology has made a major breakthrough. The field of biological therapy has now become an important development direction of clinical treatment in the future. In order to promote the development of clinical research and industrialization of biological therapy in the global, to build an exchange platform for researchers, clinicians and R&D, to analyze research hot spots and policy standards at home and abroad, 2019 the third Annual International Congress of Biotherapy – Japan (ICB-Japan 2019) will be held at Osaka, Japan during December 3-5, 2019. The conference will be held simultaneously with five parallel forums: Immunology: Science and Technology, Biotherapy & Immunotherapy for Diseases, Next Generation Biotherapy, Natural Products and Traditional Medicine in Immunotherapy, Industrial Innovation. The organizing committee will invite academicians, leading experts, and executives of industry leaders in the field of biological therapy around the world to visit the event to disseminate the latest research information and will present the latest research results.

Dr. Zang-Hee Cho received Ph.D. at Uppsala University (Sweden) in 1966 and has been faculty at the University of Stockholm and University of California-Los Angeles. In 1979, Dr. Cho moved to Columbia University as a Professor of Radiology (Physics) and served as a co-Director of Columbia University Imaging Center until 1984 before he joined University of California, Irvine (UCI). Since 1985, Dr. Cho was the Professor of Radiological Science at University of California at Irvine until 2006. From 2006 to 2014, Professor Cho, the University Professor at the Neuroscience Research Institute, Gachon University of Medicine & Science, Incheon, Korea. Dr. Cho moved to Advanced Institutes of Convergence Technology (AICT), Seoul National University, as a Distinguished Research Fellow, since 2015. Professor Cho has been a pioneer in Positron Emission Tomography (PET) and Magnetic Resonance Imaging since the inception of the computerized tomography (CT) in 1972. He was the first one who pioneered world’s first "Ring PET" in 1975 and its nuclear detector "Bismuth Germanate Oxide (BGO)" in 1976, both of which revolutionized modern brain-imaging. More recently, professor Cho pioneered the first PET-MRI (Proteomics 2008) demonstrating that in-vivo submillimeter high resolution molecular imaging is possible. This pioneering work now accepted as an important new approach to the molecular imaging in human brain imaging in-vivo. Among the numerous honors and awards, Professor Cho was elected as a member of the US National Academy of Sciences- Institute of Medicine in 1997.

Dr. George R. Lee received his medical degree from the Medical College of Georgia. He subsequently completed his internship in internal medicine at the University of Alabama, School of Medicine and his neurology residency at Vanderbilt University Medical Center. He continued his training at Vanderbilt University as a clinical neurophysiology fellow and served as the chief fellow. He currently holds an appointed position as Assistant Clinical Professor of Neurology with the Department of Neurology at Vanderbilt University Medical Center. He is the president and chairman of the board for Real Time Neuromonitoring Associates, PC and affiliated entities. He also serves as the medical director of the Vanderbilt Neurodiagnostic Technologist Training Program for which he helped found and obtain accreditation. His clinical focus is on providing intraoperative neuromonitoring and neurodiagnostic studies. Dr. Lee maintains licensure in Tennessee and 46 other states plus the District of Columbia. He has served on the Board of Directors of the American Society of Neurophysiological Monitoring (ASNM) and as its president and chairman of the board. He also has served on the board of the Tennessee Medical Association, board of Tennessee Medical Education Fund, Independent Medicine's Political Action Committee of Tennessee (IMPACT), the Tennessee Physician Leadership College Steering Committee, and the national Committee on Accreditation for Education in Neurodiagnostic Technology (CoA-NDT). He frequently presents at national and international conferences on the topics of intraoperative neuromonitoring practices, quality, evidence, medicolegal, and business. He has received leadership awards by the American Medical Association and the American Academy of Neurology and most recently received an outstanding entrepreneur award from Emory University.

Dr. Seabrook joined Janssen Pharmaceutical Companies of Johnson & Johnson in 2012 and is currently based at the J&J Innovation Center, South San Francisco, California. His role as the Global Lead for Neuroscience External Innovation is to create and implement the external innovation plan to deliver the Neuroscience Therapeutic Area R&D Strategy. He has 28 years of drug discovery experience that includes preclinical research on marketed products and candidates in clinical development. Previously, Guy was part of Eli Lilly’s Global External Research & Development organization where he led the GER&D team for the Lilly Bio-Medicines Business Unit. Formerly, at Merck & Co, he was the Head of the West Point Department of Alzheimer's disease Research. Guy graduated with a Ph.D. in Zoology from the University of Nottingham UK (1987) and completed his postdoctoral research at the University of Miami School of Medicine USA. He is a member of the British Pharmacological Society, The Physiological Society UK, and Biophysical Society, and has published over 90 peer reviewed papers and patent filings in the field.
Renowned Speakers of Previous Events
Dr. Mingde Xia
Senior Director
Johnson & Johnson Asia Pacific innovation center, China
Dr. Jacques Dumas
Sanofi, France
Dr. Jinghe Xu
Deputy Director
State Drug Administration, China
Dr. Thomas J. Webster
Art Zafirpoulo Chair
Northeastern University, USA
Dr. Steven J. Swanson
Senior Vice President
Immuno Cellular Therapeutics, Ltd., USA
Dr. Fangliang Zhang
GenScript Biotech Corp., China
Dr. Victor Levitsky
Vice President & Head
Molecular Partners AG, Switzerland
Ms. Robin Barbour
Prothena Corporation, USA
Mr. Scott Ohanesian
Senior Vice President
QuickSTAT - Global Life Science Logistics, USA
Dr. Fatih M. Uckun
Chief Medical Officer
Oncotelic, Inc., USA
Dr. David Rabuka
Global Head of R&D
Catalent Biologics, USA
Dr. Xun Zhu
Professor & Dean
Jilin University, China
Mr. Nick Zhang
Chairman & CEO
QIAGEN (Suzhou) Translational Medicine Co. Ltd., China
Dr. Jeiwook Chae
Chief Business Development Officer & Vice President
LegoChem Biosciences Inc., South Korea
Dr. Sven Loebrich
Senior Development Scientist
ImmunoGen Inc, USA
Dr. Jing Li
Senior Vice President
WuXi Biologics, China
Dr. Dan Zhang
Chairman & CEO
Fountain Medical Development Ltd., China
Jr. William R. Alley
Senior Scientist
Waters Corp., USA
Dr. Cuiying Shao
Vice President
GenScript Biotech Corp., China
Dr. Kechun Li
Beijing Yusen Equity Investment Company, Ltd., China
Dr. Jing Li
Pharmacodia, China
Dr. Youling Wu
Zhejiang Teruisi Pharmacuticals Inc., China
Dr. Danyi Wen
Shanghai Lide Biotechnology Co., Ltd., China
Dr. Qun (Max) Dang
Vice President of R&D
Qilu Pharmaceutical Co., Ltd., China
Exhibition and Poster

As part of the 2019 International Congress of Biotherapy – Japan, an exhibition space will provide a unique opportunity for exhibitors to showcase their products and services to participants with interests in all areas of biotherapy. Developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent and repeated opportunities for delegates to visit the exhibits.
Exhibitors' advantages
• The exhibition will be visited by participants of the conference it means by your authentic target group from Japan and other countries.
• The exhibitors have the opportunity to present their exhibits more detailed, and have the opportunity for longer discussion with inquiring visitors – in most cases specialists – than during session discussions.


Exhibition Date:
Set-up date: December 2, 2019
Show dates: December 3-5, 2019 09:00-18:00
Place: Osaka, Japan

Hosting Organization
National Foreign Experts Databank of MOST (Dalian Branch)
Satellite Conferences
Media Partners
TechNet Communitiesn#E9BA0C NEW 270813

In order to gather more excellent scholars and bring a larger scale of conference, the organizing committee has decided to combine the 3rd ICB-Japan 2019 with the 11th Annual World DNA and Genome Day (WDD-2020), which will be held during April 25-28, 2020 in Dalian, China. WDD-2020 is a larger celebration that plan to invite 10 Nobel Prize laureates and 1000+ speakers to share their insights and fantastic ideas. You could check the website for more details:


Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2018-2019 BIT Congress Inc.